
ViewRay VRAY
Quarterly report 2023-Q1
added 05-11-2023
ViewRay Total Assets 2011-2026 | VRAY
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets ViewRay
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 271 M | 322 M | 262 M | 350 M | 295 M | 136 M | 48.8 M | 52.2 M | 10.4 K | 5.73 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 350 M | 5.73 K | 174 M |
Quarterly Total Assets ViewRay
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 233 M | 271 M | - | - | 298 M | 322 M | 260 M | 274 M | 288 M | 262 M | 262 M | 262 M | 262 M | 350 M | 350 M | 350 M | 350 M | 295 M | 295 M | 295 M | 295 M | 136 M | 136 M | 136 M | 136 M | 48.8 M | 48.8 M | 48.8 M | 48.8 M | 52.2 M | 52.2 M | 52.2 M | 52.2 M | 34.1 M | 34.1 M | 10.4 K | 10.4 K | 5.73 K | 5.73 K | 5.73 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 350 M | 5.73 K | 173 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | ||
|
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
791 M | $ 7.75 | 10.8 % | $ 1.16 B | ||
|
EDAP TMS S.A.
EDAP
|
77.2 M | $ 4.22 | 17.39 % | $ 158 M | ||
|
Aziyo Biologics
AZYO
|
62.4 M | - | 1.37 % | $ 20.5 M | ||
|
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | ||
|
BioSig Technologies
BSGM
|
188 M | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | ||
|
Helius Medical Technologies
HSDT
|
7.69 M | $ 2.19 | -1.35 % | $ 1.33 M | ||
|
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
97.7 M | $ 11.92 | 3.92 % | $ 338 M | ||
|
OrthoPediatrics Corp.
KIDS
|
509 M | $ 17.58 | 2.69 % | $ 412 M | ||
|
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | ||
|
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | ||
|
LENSAR
LNSR
|
71.4 M | $ 5.34 | -0.84 % | $ 63.9 M | ||
|
Cytosorbents Corporation
CTSO
|
44.2 M | $ 0.58 | 1.75 % | $ 36.1 M | ||
|
LivaNova PLC
LIVN
|
2.61 B | $ 69.97 | 5.6 % | $ 3.82 B | ||
|
Delcath Systems
DCTH
|
124 M | $ 11.38 | 1.07 % | $ 408 M | ||
|
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M | ||
|
IRIDEX Corporation
IRIX
|
29.2 M | $ 1.04 | 0.04 % | $ 17.6 M | ||
|
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
132 M | - | - | $ 10.2 M | ||
|
Myomo
MYO
|
38.6 M | $ 0.88 | 3.06 % | $ 36.8 M | ||
|
Electromed
ELMD
|
53.8 M | $ 26.74 | 3.06 % | $ 226 M | ||
|
Orthofix Medical
OFIX
|
851 M | $ 12.19 | - | $ 483 M | ||
|
Butterfly Network
BFLY
|
256 M | $ 4.38 | -3.74 % | $ 927 M | ||
|
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
39.4 M | - | -0.97 % | $ 54.4 M | ||
|
Insulet Corporation
PODD
|
3.19 B | $ 161.81 | 6.96 % | $ 11.4 B | ||
|
GBS
GBS
|
8.25 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
5.3 B | $ 89.04 | -0.19 % | $ 12 B | ||
|
Sintx Technologies
SINT
|
9.51 M | $ 2.44 | 1.87 % | $ 6.77 M | ||
|
CONMED Corporation
CNMD
|
2.33 B | $ 38.02 | 1.77 % | $ 1.18 B | ||
|
Inspire Medical Systems
INSP
|
907 M | $ 47.19 | 3.11 % | $ 1.39 B | ||
|
Integer Holdings Corporation
ITGR
|
3.41 B | $ 87.9 | 1.88 % | $ 3.05 B | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
Stryker Corporation
SYK
|
47.8 B | $ 296.38 | 1.41 % | $ 113 B | ||
|
Edwards Lifesciences Corporation
EW
|
13.7 B | $ 83.75 | 0.67 % | $ 49 B | ||
|
Tandem Diabetes Care
TNDM
|
881 M | $ 18.85 | 4.52 % | $ 1.28 B | ||
|
Tactile Systems Technology
TCMD
|
274 M | $ 26.71 | 5.55 % | $ 611 M | ||
|
TransMedics Group
TMDX
|
1.07 B | $ 76.47 | 4.88 % | $ 2.6 B |